- Barrons.com•7 days ago
After surveying doctors on the preferred hepatitis-C treatments, Baird's Brian Skorney and Neena Bitritto-Garg contend that Gilead Sciences (GILD) is likely to maintain its dominance over AbbVie (ABBV), Merck (MRK) and Johnson & Johnson (JNJ) but in what appears to be a shrinking market. In conjunction with script trends, physicians indicate that the market for treatment-eligible, easily accessible Hep C patients is shrinking, but that Gilead's share of the shrinking pie is continuing to grow.
- Zacks•12 days ago
Achillion Pharmaceuticals (ACHN) is seeing solid earnings estimate revision activity, and is in great company from a Zacks Industry Rank perspective.
- GlobeNewswire•14 days agoAchillion Announces Upcoming Presentation of Interim Phase 2a Results From the Janssen Sponsored Trial of Odalasvir, AL-335 and Simeprevir at the European Association for the Study of the Liver (EASL) Special Conference
NEW HAVEN, Conn., Aug. 11, 2016-- Achillion Pharmaceuticals, Inc. announced today that interim results from an ongoing phase 2 a clinical trial, being conducted by Alios BioPharma Inc., part of the Janssen ...
Achillion Pharmaceuticals, Inc. (ACHN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||8.63 x 400|
|Ask||9.33 x 300|
|Day's Range||8.60 - 9.49|
|52wk Range||5.57 - 10.95|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||175.51|
|Avg Vol (3m)||1,308,570|
|Dividend & Yield||N/A (N/A)|